Byczy
Eli Lilly's stock rises as Q1 earnings beat expectations and 2026 guidance is raised.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Eli Lilly reported strong first-quarter 2026 results, with adjusted earnings per share of $8.55, surpassing the consensus estimate of $7.06. The company also raised its full-year earnings guidance to a range of $35.50 to $37.00 per share, up from the previous $33.50 to $35.00. This positive performance is driven by robust sales of its GLP-1 drugs, Mounjaro and Zepbound, which saw significant year-over-year growth.
Kluczowe punkty
- Eli Lilly's Q1 2026 adjusted earnings per share of $8.55 exceeded expectations of $7.06.
- The company raised its 2026 earnings guidance to $35.50–$37.00 per share, up from $33.50–$35.00.
- Sales of Mounjaro and Zepbound increased by 125% and 56% year-over-year, respectively.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
